Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate E Broderick

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
The Journal of Infectious Diseases|January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialKimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Cell Reports. Medicine|October 4, 2021
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge modelAmi Patel, Jewell N Walters, Emma L Reuschel, et al.
Nature Communications|May 21, 2020
Immunogenicity of a DNA vaccine candidate for COVID-19Trevor R F Smith, Ami Patel, Stephanie Ramos, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
The Journal of Infectious Diseases|January 26, 2022
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialKimberly A Kraynyak, Elliott Blackwood, Joseph Agnes, et al.
Eclinicalmedicine|January 4, 2021
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trialPablo Tebas, ShuPing Yang, Jean D Boyer, et al.
Cell Reports. Medicine|October 4, 2021
Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge modelAmi Patel, Jewell N Walters, Emma L Reuschel, et al.
Nature Communications|May 21, 2020
Immunogenicity of a DNA vaccine candidate for COVID-19Trevor R F Smith, Ami Patel, Stephanie Ramos, et al.
Pageof 11